Sutro biopharma, inc. (STRO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenues (including amounts from related parties of $2,813 during the three months ended March 31, 2020, and $4,916 during the three months ended March 31, 2019)

7,152

11,305

12,277

10,525

8,629

19,086

7,836

5,704

5,793

-

Total revenue

-

-

-

-

-

-

-

-

-

17,499

Operating expenses
Research and development

17,619

17,392

16,897

16,143

15,180

14,787

12,642

13,751

13,082

13,669

General and administrative

8,713

8,695

8,115

8,067

7,715

7,574

5,351

4,041

4,414

4,895

Total operating expenses

26,332

26,087

25,012

24,210

22,895

22,361

17,993

17,792

17,496

18,564

Loss from operations

-19,180

-14,782

-12,735

-13,685

-14,266

-3,275

-10,157

-12,088

-11,703

-1,065

Interest income

641

810

964

1,124

1,176

1,133

403

40

40

62

Interest and other income (expense), net

-1,056

-

-

-

-1,160

-

-

-

-

-

Interest and other expense, net

-

-

1,141

1,232

-

-

483

-507

383

-

Interest expense

-

-

-

-

-

-

-

-

-

235

Other income (expense), net

-

-

-

-

-

-

-

-

-

-180

Net loss

-19,595

-14,789

-12,912

-13,793

-14,250

-1,493

-10,237

-11,541

-12,046

-1,418

Net loss per share

-0.84

-0.65

-0.56

-0.60

-0.62

65.05

-21.26

-24.17

-25.75

-3.14

Weighted-average shares used in computing net loss per share

23,197

23,095

22,946

22,926

22,865

21,608

481

477

467

451